NASDAQ · RCEL
Avita Medical Inc.
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
Loading market information…
NASDAQ · APYX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Apyx Medical Corporation’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Apyx Medical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.10+16.67% vs estimate | $9.43M+1.04% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.12+7.69% vs estimate | $14.22M+44.02% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.14+6.67% vs estimate | $11.49M-11.75% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $6.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.71+$0.21 (+1.27%)
Avita Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
$61.60-$1.59 (-2.52%)
Pro-Dex, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
$3.65$0.00 (0.0%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$1.14$0.00 (0.0%)
Vivani Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$2.06+$0.03 (+1.48%)
Sera Prognostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.49% below the high.
$0.29+$0.00 (+1.54%)
Xtant Medical Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.43% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
